Development gp_j5unjv 2018-01-18T09:40:39+00:00

Development

Glycadia’s experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy and cardiovascular disease.

Product Pipeline

See the full pipeline for Glycadia’s proprietary new chemical entities.

Clinical Trials

Glycadia has completed Phase Ia and Phase Ib/IIa clinical trials with its lead compound, GLY-230, and is preparing for additional Phase II trials of GLY-230 in patients with diabetes at risk for diabetic nephropathy and diabetic retinopathy.

Milestones

Glycadia, Inc.’s awards and latest achievements.